Laura Ford retweeted
Replying to @mahesh_shenai
@mahesh_shenai, Although we have never met, I addressed Dr. Mallika Mundkur at the @FDA's CNPV public meeting, whom I understand is your wife.
After reading nearly 20 of your posts concerning Huntington’s disease (HD) and AMT-130, I have to ask: Are you evaluating the totality of the evidence, or predominantly searching for reasons to discount it?
You repeatedly express hope that you will someday treat Huntington’s disease patients. But how much direct experience have you had with our community? Have you spent meaningful time with symptomatic patients across disease stages, witnessed their progressive neurological decline, or spoken with families about their risk tolerance?
I ask because I have.
HD has devastated three generations of my family. My grandmother died after years of suffering. Her chorea was so severe that she wore padded mittens for nearly four years to prevent her involuntary movements from dislodging her feeding tube.
I was nearly my daughter’s age when my grandmother developed symptoms. Now both my daughter and son are watching their grandfather and aunt experience the same disease. My father is in the middle stages of Huntington’s disease, while my aunt is further along in its devastating progression. As a mother, I live with the painful reality that my children may one day witness this same deterioration in me—or, even more heartbreaking, experience it themselves.
What I witnessed as a little girl, my children are witnessing today. Different generations, the same devastating cycle we are desperately trying to break.
The psychological consequences are equally profound. A fellow Michigander and HD advocate recently lost her father to suicide. Another Michigan chapter board member nearly lost her niece, and several HD friends have lost loved ones to suicide. Suicide risk among people with Huntington’s disease is substantially higher than in the general population.
Why? Imagine caring for someone you love while witnessing years of relentless neurological deterioration, all while knowing you could face the same fate. And even if you escape inheriting the mutation, you may carry the lifelong burden of survivor’s guilt as those you love continue to suffer. This is the profound, multigenerational trauma of Huntington’s disease.
More than 40,000 Americans live with HD, and over 200,000 are at risk. Those figures do not include the countless caregivers and relatives whose lives are also affected.
Your anecdote about a surgeon with another movement disorder reinventing his professional life was particularly revealing. When I read it, I immediately questioned your firsthand understanding of HD.
HD does not afford patients the luxury of simply reinventing their lives. It progressively damages the brain circuits responsible for cognition, judgment, behavior, movement, and independence. Symptoms can worsen over 10–25 years, gradually taking away the ability to work, communicate, maintain relationships, swallow, walk, talk, and care for oneself.
The ability to reinvent one's life requires precisely the neurological capacities HD progressively destroys. HD takes away the ability to meaningfully participate in life altogether.
The 2024 HD Symptoms and Treatment Impact Survey found that nearly three-quarters of respondents would accept treatment risks for five years without progression, while approximately 35% would accept risks for even three years.
Three more years raising children. Five more years working, communicating, remembering, and living independently. More birthdays, graduations, and time with family.
Then consider the economic consequences of inaction. Over 10–25 years, HD families will face neurologists, psychiatrists, hospitalizations, expensive chorea and psychiatric medications, physical and occupational therapy, speech and swallowing therapy, mobility equipment, home modifications, specialized residential care, and eventually around-the-clock assistance.
HD removes two people from the workforce: the patient and the family member who becomes their caregiver. Families lose wages, insurance benefits, retirement savings, and years of financial security. Many conventional care facilities lack the specialized neurological and behavioral resources required for HD, leaving families with limited options.
These costs accumulate across households, employers, Medicare, Medicaid, disability programs, and society.
When evaluating the risks and costs of treatment, why is the cost of inaction so often treated as though it were zero?
If AMT-130 meaningfully preserves independence, the potential economic and societal benefits deserve consideration.
You have described yourself as one of approximately 80 U.S. neurosurgeons with expertise relevant to this procedure. If AMT-130 does not meet your personal threshold for clinical adoption, that is your judgment. But your threshold is not the FDA's regulatory standard, nor should it determine the choices available to every informed patient and qualified physician.
Other neurosurgeons may recognize the broader significance of this investigational gene therapy. If its clinical benefits are confirmed, AMT-130 could help transform how we approach inherited neurodegenerative disorders beyond HD.
Regarding surgical risk, stereotactic neurosurgery has been performed in humans since 1947. Trial experience suggests the procedure has generally been tolerated.
But the question is not whether neurosurgery carries risk. It does. The question is whether those risks are acceptable relative to the potential benefit for patients facing a progressive, fatal disease without an approved disease-modifying treatment.
Your professional risks and our personal risks may look entirely different.
For you, this is a discussion of procedural complications, evidence, and professional responsibility. For us, it is progressive neurological deterioration, dependency, and premature death.
The reported AMT-130 findings, including favorable Total Functional Capacity trajectories compared with external controls, deserve serious consideration. TFC measures employment, financial management, domestic responsibilities, daily living, and care requirements. It measures the independence HD progressively takes away.
Scientific skepticism is essential, but it must be applied symmetrically.
Our community has also been wounded by regulatory rhetoric. @VPrasadMDMPH, your wife’s former boss, recently compared patients pursuing unproven treatments to a drowning person reaching for a blade. Regardless of the intended scientific warning, such language risks reducing informed, deeply personal benefit-risk decisions to acts of desperation, overlooking the devastating consequences patients and families face without treatment.
Our willingness to accept uncertainty is not desperation. It reflects a rational understanding of what HD will otherwise take from us.
Imagine watching someone you love progressively lose the ability to think, communicate, walk, swallow, or even recognize the people they love most. Now imagine living with the knowledge that the same devastating disease could one day affect you, your children, your siblings, or generations of your extended family. This is the reality of Huntington’s disease.
What would a few additional years together mean? What would you do to break the cycle?
I am not asking you to abandon scientific standards. I am asking you to recognize that the consequences of waiting are as real as the risks of treatment.
The absence of treatment is not the absence of risk. It is continued disease progression, escalating dependency, enormous psychological and economic suffering, and irreversible neurological loss.
You may see an investigational neurosurgical procedure that has not met your preferred evidentiary threshold. We see a potential opportunity to preserve the ability to think, communicate, work, love, and remain present in our families' lives.
We are asking for scientific judgment that accounts for the full reality of Huntington’s disease.
P.S. Go Blue! 〽️💙💛
#HuntingtonsDisease
#RareDisease
Laura Ford retweeted
Replying to @FDA
Thank you, @US_FDA, for recognizing that rare diseases demand innovative regulatory approaches grounded in rigorous science and meaningful patient engagement. This initiative has the potential to be transformative.
Please make Huntington’s disease a priority.
With investigational therapies like uniQure's AMT-130, we have an opportunity to demonstrate how fit-for-purpose evidence, innovative trial designs, natural history data, and meaningful patient perspectives can inform rigorous, scientifically sound regulatory decisions.
The implications extend far beyond Huntington’s disease. With approximately 95% of rare diseases lacking an FDA-approved treatment, a framework that aligns evidentiary expectations with the scientific realities of small populations and progressive diseases could fundamentally reshape therapeutic development.
For patients facing irreversible neurological decline, time is not merely a regulatory consideration. It represents cognitive function, independence, livelihoods, and precious years with loved ones that cannot be recovered.
The true measure of this initiative will be its ability to translate regulatory innovation into meaningful therapeutic progress.
Please ensure patients and families have a genuine seat at the table as this framework evolves. The Huntington’s disease community stands ready to contribute.
💙💜
#HuntingtonsDisease
#RareDisease
Laura Ford retweeted
@VPrasadMDMPH, calling United States senators “dumb” is incredibly disrespectful to the people who serve our government and to the legislative process itself.
So much hubris!
I listened to your comments, and I feel compelled to respond.
I am a daughter, a niece, a granddaughter, and someone who lives with the reality that Huntington’s disease could affect me. More than 200,000 Americans are at risk of Huntington’s disease. Behind that number are families like mine.
My dad has Huntington’s disease. My aunt has Huntington’s disease. My grandmother died from it.
Huntington’s disease is destroying my family, and I live with the reality that it could one day destroy my future, too.
So when you suggest that the push for Huntington’s disease therapies is being driven by pharma or lobbyists, I need you to understand who you are talking about.
We are patients. We are families. We are caregivers. We are people who have watched this disease take our loved ones from us.
We have every right to meet with legislators, write letters, sign petitions, and demand that our voices be heard.
And it is deeply dismissive to suggest that families advocating for a potential treatment are somehow being manipulated by industry.
While serving as CBER director, you spoke to reporters on the condition of anonymity about an investigational Huntington’s disease therapy that was under active FDA review. You characterized the treatment as a “failed therapy,” and you were subsequently identified as that official.
The Huntington’s disease community responded by mobilizing.
Nearly 50,000 people signed petitions urging the FDA to preserve a path forward for this potentially disease-modifying therapy.
Those signatures weren’t generated by a pharmaceutical company.
They came from people like me.
People who know exactly what Huntington’s disease looks like.
Now, in this podcast, you have once again publicly dismissed a therapy that has shown significant slowing of disease progression in clinical data, results the Huntington’s disease community has waited decades to see.
There is a profound difference between scrutinizing the science and publicly disparaging an ongoing Huntington’s disease clinical trial, especially when patients and families are living every day with the consequences of this disease.
And when you joke about “snake oil,” remember this:
Huntington’s disease is the snake.
I watched my grandmother die from it.
I am watching my dad live with its devastating effects.
I am watching my aunt live with its devastating effects.
And I live with the reality that it could one day come for me, and my family.
So if something you call “snake oil” ultimately proves capable of slowing this disease, yes, we are going to fight with all our might for the opportunity to have it fairly evaluated.
Not because we are naïve.
Not because pharma told us what to believe.
Not because a lobbyist told us what to say.
Because we live with Huntington’s disease.
And when you talk about a $1.4–$4 million price tag, I think the economic question needs to be much bigger:
How much does Huntington’s disease cost this country when we do nothing?
What is the value of keeping someone independent for additional years?
Keeping them working?
Keeping their spouse or caregiver in the workforce?
Delaying institutionalization?
Reducing hospitalizations, long-term care, and the enormous unpaid burden placed on American families?
A therapy that meaningfully delays disability could have an economic benefit far beyond the cost of the therapy itself.
We aren’t asking to lower the scientific bar.
We’re asking you to remember who that bar is supposed to serve.
The patients.
The families.
The caregivers.
And the future generations who deserve a chance at a different outcome.
Huntington’s disease is the snake. We are simply fighting for the chance to stop it.
Last week I had the honor of delivering public comment at the Reagan-Udall Foundation/FDA Drug Repurposing meeting in DC, speaking to the evidence gaps and regulatory barriers that keep promising therapies out of reach for people living with Huntington's disease. 🧵
1
1
27
Grateful to Reagan-Udall and FDA for creating space where patient and family voices sit alongside researchers and regulators as experts in their own right. Good policy gets stronger when it's shaped with the people living the disease, not just for them.
1
3
No one fights Huntington's disease alone. #StandSpeakAdvocate #HuntingtonsDisease #DrugRepurposing #RareDisease
10
Friends in the rare disease community--the NEJM (the world's most widely read, cited, and influential general medical periodical) outlines why we need to be concerned about this OMB proposed rule to restructure federal financial assistance oversight. nejm.org/doi/full/10.1056/NE…
1
25
Laura Ford retweeted
Replying to @KatyTalento
I’m glad you put a “bias alert” at the beginning, because at least that part is honest:
“I’m on a side. I’m not impartial or fair. I’m biased with a punch-anyone-in-the-face-who-talks-shit-about-my-family kind of bias.”
The problem is that this bias seems to extend to dismissing rare disease patients and advocates before ever actually listening to them.
When you reduce rare disease patient groups to people simply being “told by Pharma” that the FDA is delaying some “wonder drug,” that’s not thoughtful analysis. That’s caricature. And it’s insulting.
Patients in communities like Huntington’s disease are not naïve props being manipulated into outrage. Many of us have spent YEARS - some of us decades - immersed in this work. We’ve participated in clinical trials, sat in FDA meetings, and helped shape patient-focused drug development. We've learned the science because our lives and families depend on understanding it.
You do not have to agree with every patient advocate. You can absolutely question data, regulatory decisions, company claims, or trial design.
However, dismissing patients as if we are incapable of independent thought because our perspective doesn’t align with yours is arrogance, not objectivity.
And frankly, the assumption that desperate patients are too emotional, too compromised, or too uninformed to think critically for themselves says far more about the person making that assumption than the patients being dismissed.
Yes, patients are emotional. Of course we are! We are watching people we love decline in real time. Some of us like myself are living this in our own bodies. We understand exactly what lost time means.
Emotion does NOT negate intelligence. It does NOT erase lived expertise. And it certainly does not mean patients are incapable of understanding risk-benefit tradeoffs in diseases that are relentlessly progressive and ultimately fatal.
What’s actually dangerous is a worldview that treats patient voices as disposable the moment they become inconvenient.
If your starting assumption is that rare disease communities are simply being manipulated rather than engaging thoughtfully with extraordinarily complex issues, then you (and @DrMakaryFDA and @VPrasadMDMPH) were never actually trying to hear us in the first place.
Inspired by the advocates, families, and community members, five Huntington’s disease organizations came together today to champion the future of rare disease innovation at the FDA.
Together, we look forward to strengthening our partnership with the FDA to bring renewed hope, urgency, and patient-centered progress to Huntington’s disease.
Every day matters for HD families — and we will continue advocating together for a brighter future. 💙
#HuntingtonsDisease #RareDisease #PatientAdvocacy #HDCommunity @POTUS @realDonaldTrump @WhiteHouse @US_FDA @FDACBER @FDACDERDirector @RFKJr_Official
Laura Ford retweeted
Signed by myself and a couple others in the rare disease community💙 honored to represent multiple rare diseases @POTUS @realDonaldTrump @RFKJr_Official
realclearhealth.com/blog/202…
Laura Ford retweeted
The FDA Commissioner role is open. This is a pivotal moment for American medicine — & for American patients.
Here’s what I believe the next Commissioner should stand for. Not as a wish list. As a baseline.
🔬 1. BRING BACK THE ADCOMS — AND MAKE THEM COUNT.
Advisory Committee meetings are one of the FDA’s most powerful tools for transparency. They should return in full force. Open. Public. And real.
Patients, doctors, scientists, advocates, & skeptics should all be able to speak. But if you want to speak, you fill out a financial conflict-of-interest form under penalty of perjury — & you read it out loud at the podium before you say another word. Every single person.
And if the issues are complex and the science requires more than one day, then take the time. Don’t cut people off because the schedule says so. The public deserves to see exactly how these decisions are made. Real transparency builds real trust.
⚖️ 2. STOP ASKING ONLY “IS IT SAFE ENOUGH TO APPROVE?” — START ASKING “WHAT HAPPENS IF WE DON’T?”
For rare diseases. For serious conditions with no good options. For patients who don’t have ten years to wait for traditional trials that may never be feasible.
Every regulatory decision carries two risks: the risk of approving something, and the risk of not approving it. Both are real. Both affect real people.
When traditional gold-standard trials aren’t practical, we should still be able to move with urgency — but only when paired with strong post-approval commitments and rigorous safety monitoring. We can give desperate patients a chance without abandoning scientific integrity.
🇺🇸 3. THE FDA’S ONLY CLIENT IS THE AMERICAN PATIENT. FULL STOP.
The FDA exists to serve patients — not outside interests or external pressures of any kind.
It must continue protecting the public from products that carry real, known risks but offer no meaningful clinical benefit.
At the same time, when there is credible evidence that a treatment can help patients with serious conditions, Americans and their physicians should be trusted to make informed decisions once they have complete and honest information about the risks, benefits, and alternatives.
The FDA’s job is to make sure the science is sound and the information is clear. Then let patients and doctors do what’s best for them.
These principles matter because the FDA’s decisions affect every family in this country.
Note: This is a simple social media post and not a massive policy document. The issues are FAR more nuanced, there are challenges and risks with each of the things I said above, and I recognize that. But it's intended to serve as a discussion starter. We must always strive to improve, and we can when we have open debate and dialogue.
Laura Ford retweeted
AMT-130 represents the most promising disease-modifying approaches currently being studied in Huntington’s disease, aiming to target the underlying genetic driver rather than just symptoms. In Huntington’s disease, where there are no approved treatments that slow progression and time is running out for patients, regulators should allow more flexibility and act with urgency. The goal isn’t to lower standards, but to keep the pace of review aligned with the pace of the disease.
That’s why it’s important to be precise with the data. Small exploratory cohorts (like n=17) and early 12-month readouts are not designed to determine disease acceleration or efficacy in Huntington’s. HD is slow, variable, and requires longer observation windows to interpret true treatment effects.
This is also why the 3-year follow-up data is so important. Long-term trends rather than early short-term fluctuations are what shows AMT-130 produces durable slowing of neurodegeneration.
What often gets lost in these debates is the human reality behind the science.
Over 50,000 people in the Huntington’s disease community have signed petitions supporting faster access for therapies like AMT-130. This is not driven by “big pharma,” but by patients, families, caregivers, and volunteers living with a relentlessly progressive disease and limited options. There is no financial incentive, only urgency.
In 2024, many of us met with the FDA in Maryland through the HDSA EL-PFDD meeting. I personally shared my story and saw firsthand how deeply these experiences land with regulators. We were told patient voices mattered and that accelerating pathways for serious neurodegenerative disease was a priority.
In the 2024 HDSA survey, 3/4 of respondents would accept meaningful risk for 5 years without progression, and ~35% would accept risk even for 3 years of halted disease.
We are not “moneyed interests.” We are patients and families asking for decisions grounded in full, long-term evidence, and for regulatory flexibility and urgency that match the pace and severity of this disease.
Laura Ford retweeted
I didn't get the chance to say what I wanted earlier because my kids needed my attention and I've been packing and getting ready to leave for the @Help4HDI #HIPE event in Baltimore this weekend. But this article really got me worked up.
I appreciate the acknowledgment from Dr. Buracchio that the “plausible mechanism framework” could extend beyond individualized therapies and shouldn’t disadvantage diseases like #HuntingtonsDisease.
But the reality is, we are ALREADY seeing a double standard.
The FDA is signaling openness to flexible, mechanism-based approaches while rejecting those same principles when applied to Huntington’s and AMT-130.
That’s not just confusing;
It’s UNACCEPTABLE for a rare disease community that depends on regulatory consistency.
The comparison to “Baby KJ” highlights a fundamental disconnect:
In pediatric conditions, success is defined by improvement - meeting milestones, gaining abilities.
Huntington’s does not work that way. This is a progressive neurodegenerative disease where the most meaningful outcome is slowing decline or maintaining function longer than expected.
In HD, stability IS improvement.
So when the FDA says it needs a “clear and distinct” effect from natural history, the question is:
What does that look like in a disease where decline is the baseline?
Because if converging evidence across clinical measures like cUHDRS, biomarkers like NfL, and natural history comparisons isn’t enough in HD, then the standard isn’t just high - It’s completely misaligned with the biology of the disease.
And when standards are misaligned, patients pay the price.
This isn’t about asking for exceptions. It’s about expecting the @US_FDA to apply its own stated principles consistently and in a way that reflects the realities of the diseases it regulates.
Because in Huntington’s disease, delay isn’t neutral.
Delay is decline.
Decline is irreversible.
And irreversible means time we don’t get back. #TimeMatters #DelayStealsTime #ActWithUrgency
@adamfeuerstein @SenateAging @SenRonJohnson @SenRickScott @SenGillibrand @RepAuchincloss @FDACBER @DrMakaryFDA @realDonaldTrump @WhiteHouse @fdacder @FDACDERDirector @houmanhemmati
“Justice and equity don't come from telling troubled communities what they need to do, but from listening to those having trouble and working together to forge solutions.…”
DOE Seeks Public Input on Environmental Justice Strategic Plan energy.gov/justice/articles/…
I’m thrilled to be starting a new adventure as Grants Program Specialist at @foreversolar. Can't wait to dive into new opportunities to forge partnerships for people and the planet. #SolarIndustry #ConstantlyGrowing #ShakingThingsUp #GoodEnergy
1
48
After an incredible 20-year journey as part of the @Accokeek staff, I've transitioned to a new chapter, now caring as a volunteer for @PiscatawayPark Indigenous cultural landscape and its rich stories. I’ll be forever grateful for the lessons learned on this landscape!
2
43
Holy Week - The Atlantic. “Fifty-five years ago today, Martin Luther King Jr. was assassinated. In stories about the civil-rights movement, what happened next is often overlooked. But the week that followed his killing changed the course of history….” theatlantic.com/podcasts/hol…











